share_log

Hangzhou Biotest BiotechLtd's (SHSE:688767) Shareholders May Want To Dig Deeper Than Statutory Profit

杭州バイオテストバイオテクノロジー株式会社(SHSE:688767)の株主は、法定利益以上の詳細情報を追求したいかもしれません。

Simply Wall St ·  09/05 18:34

The stock price didn't jump after Hangzhou Biotest Biotech Co.,Ltd. (SHSE:688767) posted decent earnings last week. We think that investors might be worried about some concerning underlying factors.

big
SHSE:688767 Earnings and Revenue History September 5th 2024

The Impact Of Unusual Items On Profit

To properly understand Hangzhou Biotest BiotechLtd's profit results, we need to consider the CN¥25m gain attributed to unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. Which is hardly surprising, given the name. We can see that Hangzhou Biotest BiotechLtd's positive unusual items were quite significant relative to its profit in the year to June 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Hangzhou Biotest BiotechLtd.

Our Take On Hangzhou Biotest BiotechLtd's Profit Performance

As we discussed above, we think the significant positive unusual item makes Hangzhou Biotest BiotechLtd's earnings a poor guide to its underlying profitability. For this reason, we think that Hangzhou Biotest BiotechLtd's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. But at least holders can take some solace from the 31% EPS growth in the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. Our analysis shows 3 warning signs for Hangzhou Biotest BiotechLtd (1 can't be ignored!) and we strongly recommend you look at these before investing.

Today we've zoomed in on a single data point to better understand the nature of Hangzhou Biotest BiotechLtd's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする